Windtree Therapeutics (WINT) AI Stock Analysis

• Market Cap: $1.15M
• Dividend Yield: N/A
• Average Volume (3M): 5.47M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.91
• Revenue Growth: N/A
• EPS Growth: 94.78%
• Country: US
• Employees: 15
• Sector: Healthcare
• Sector Strength: 64
• Industry: Biotechnology
• EPS (TTM): -931.66
• Shares Outstanding: 700,000
• 10 Day Avg. Volume: 15,169,007
• 30 Day Avg. Volume: 5,473,461
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 23.55
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

Windtree Therapeutics' overall stock score reflects significant financial and technical challenges. The persistent lack of revenue and negative cash flows highlight financial instability, while the bearish technical indicators underscore ongoing market pessimism. Although a recent strategic leadership change presents a potential upside, it has yet to materially improve the company's financial outlook.

Windtree Therapeutics Business Overview & Revenue Model

Company Description

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.

How the Company Makes Money

Windtree Therapeutics generates revenue primarily through the development, commercialization, and licensing of its proprietary therapeutic products. The company aims to monetize its products by pursuing regulatory approvals in key markets, leading to product sales and distribution agreements. Additionally, Windtree may engage in partnerships or collaborations with larger pharmaceutical companies to co-develop and market its therapies, which can provide upfront payments, milestone payments, and royalties. Furthermore, the company may secure funding through grants or contracts from government agencies or research institutions, contributing to its financial sustainability and growth.

Windtree Therapeutics Financial Statement Overview

Summary

Windtree Therapeutics faces significant financial challenges, characterized by an inability to generate revenue and negative profitability metrics. The balance sheet reveals a reliance on debt, reducing financial flexibility. Cash flow issues further exacerbate financial instability, raising concerns about operational sustainability. Strategic changes may be required to improve financial health.

Income Statement

The company has consistently reported zero revenue over recent years, reflecting challenges in generating sales. Gross profit is negative, indicating costs exceed any income, and net losses persist. No revenue growth rate can be calculated due to zero revenues. EBIT and EBITDA margins are negative, highlighting significant operational inefficiencies.

Balance Sheet

The balance sheet shows a high debt-to-equity ratio, suggesting a reliance on debt financing. The return on equity is negative, reflecting ongoing losses. The equity ratio has declined over time, indicating a reduction in financial stability. However, the total assets have been maintained, suggesting some stability in asset base.

Cash Flow

Operating cash flows are negative, and free cash flow is consistently negative, indicating potential liquidity concerns. The free cash flow growth rate is negative, reflecting deteriorating cash flow performance. The company relies on financing cash flows, which could pose risks if capital markets change.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	198.00K
	Gross Profit
-67.00K	-82.00K	-1.06M	-869.00K	-638.00K	185.31K
	EBIT
-25.56M	-17.54M	-41.33M	-77.28M	-30.32M	-24.89M
	EBITDA
-9.26M	-20.16M	-39.46M	-76.64M	-31.80M	-25.87M
	Net Income Common Stockholders
-9.71M	-20.29M	-39.21M	-67.64M	-30.28M	-29.86M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
25.15M	4.32M	6.17M	22.35M	16.93M	22.58M
	Total Assets
119.40M	32.41M	37.95M	74.79M	112.89M	118.97M
	Total Debt
7.97M	16.83M	2.28M	2.89M	3.78M	6.31M
	Net Debt
-3.21M	12.51M	-3.89M	-19.45M	-13.15M	-16.27M
	Total Liabilities
51.28M	29.02M	27.94M	32.91M	43.33M	44.04M
	Stockholders Equity
68.11M	3.39M	10.01M	41.88M	69.55M	74.94M
Cash Flow		Free Cash Flow
-15.30M	-13.45M	-19.46M	-23.94M	-25.61M	-24.85M
	Operating Cash Flow
-15.28M	-13.44M	-19.45M	-23.66M	-25.32M	-24.66M
	Investing Cash Flow
-12.00K	-15.00K	197.00K	-279.00K	-291.00K	13.80M
	Financing Cash Flow
10.09M	11.60M	3.08M	29.36M	19.96M	21.77M

Windtree Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WINT, the sentiment is Negative. The current price of 1.64 is below the 20-day moving average (MA) of 2.00, below the 50-day MA of 5.04, and below the 200-day MA of 119.79, indicating a bearish trend. The MACD of -1.08 indicates Negative momentum. The RSI at 29.76 is Positive, neither overbought nor oversold. The STOCH value of 10.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for WINT.

Windtree Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KNSA	66 Neutral	$1.70B	―	-9.85%	―	56.60%	-403.56%
Sector *	49 Neutral	$6.86B	0.72	-52.93%	2.49%	20.83%	1.11%
VSTM	47 Neutral	$346.51M	―	-526.33%	―	―	14.39%
AVDL	46 Neutral	$784.63M	―	-60.44%	―	504.79%	74.24%
ACHV	37 Underperform	$99.20M	―	-409.51%	―	―	19.70%
WINT	34 Underperform	$1.15M	―	-138.34%	―	―	94.78%

Windtree Therapeutics Corporate Events

Windtree Therapeutics Strengthens Leadership Amid Strategic Shift

Windtree Therapeutics has appointed Leanne Kelly to its board of directors as an independent director and chair of the audit committee, aiming to resolve a compliance deficiency with Nasdaq’s requirements. Kelly’s extensive experience in finance and leadership across life science, technology, and e-Commerce sectors is expected to strengthen Windtree’s board as the company embarks on a new strategy to acquire small biotech firms with FDA-approved products, enhancing its market positioning.

Windtree Therapeutics Appoints Jed Latkin as New CEO

Windtree Therapeutics, Inc. announced the retirement of Craig Fraser as CEO, effective December 2024, with Jed Latkin set to take over the role. Latkin, who brings extensive experience in finance and biotech from his previous roles at ProPhase Labs and other companies, will assume leadership with a focus on leveraging his expertise to drive the company forward. His compensation package includes bonuses and equity incentives, reflecting the company’s commitment to aligning executive interests with shareholder value.